文献速递泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗姑息放疗与转移瘤

筛查性结肠镜检查与前列腺立体定向体部放疗后胃肠道毒性及生活质量的关系

Screening Colonoscopy Association With Gastrointestinal Toxicity and Quality of Life After Prostate Stereotactic Body Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2025-02-22

本研究回顾性分析接受前列腺SBRT患者的治疗前筛查性结肠镜检查(CS)结果及其与毒性和生活质量的关系。结果显示憩室病49.5%、痔疮67%、息肉48%常见,治疗前CS未延迟SBRT开始,未增加医生评定的毒性风险,也未观察到生活质量损害。作者主张对符合条件者在SBRT前进行CS。

要点

  • 治疗前筛查性结肠镜检查在前列腺SBRT患者中常见发现憩室病、痔疮和息肉。
  • 治疗前CS未延迟SBRT开始时间,也未增加医生评定的毒性风险。
  • 治疗前CS发现胃肠道病理的患者未观察到明显的生活质量损害。

核心结论

  • 治疗前筛查性结肠镜检查发现的胃肠道病理在前列腺SBRT患者中常见,但未增加毒性或损害生活质量,不排除SBRT的实施。
  • 作者主张对符合条件者在SBRT前进行筛查性结肠镜检查。

研究设计与样本

  • 回顾性分析机构数据库中接受前列腺SBRT患者的毒性和生活质量结局。
  • 详细审查治疗前结肠镜检查发现,包括憩室病、息肉切除位置和痔疮,并与SBRT后结局关联。

主要发现

  • 憩室病发生率为49.5%(n=100),痔疮为67%(n=136),息肉为48%(n=98)。
  • 超过一半的息肉切除患者至少有一个息肉从直肠乙状结肠切除。
  • 治疗前结肠镜检查未导致SBRT开始日期延迟。
  • 接受结肠镜检查更接近SBRT开始的患者,1级毒性显著更低。
  • 存在憩室病、痔疮或息肉的患者,医生评定的毒性风险未增加。

临床怎么用

  • 治疗前筛查性结肠镜检查可用于识别同步恶性肿瘤和共病胃肠道情况。
  • 在放疗前进行这些检查可避免SBRT后盆腔器械操作的必要性,后者可能导致严重毒性和瘘管形成。
  • 对符合条件者,作者主张在SBRT前进行结肠镜检查。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Screening colonoscopies (CS) performed before prostate stereotactic body radiation therapy (SBRT) allow for identifying synchronous malignancies and comorbid gastrointestinal (GI) conditions. Performing these procedures prior to radiation precludes the necessity of post-SBRT pelvic instrumentation, which may lead to severe toxicity and fistulization. We review compliance of CSs, incidence of GI pathology, and the impact of pretreatment CS findings on subsequent physician-reported toxicity and patient-reported quality of life (QoL). METHODS AND MATERIALS: We reviewed an institutional database of patients treated for prostate cancer with SBRT including toxicity and QoL outcomes. A detailed review of pretreatment CS findings was reviewed including identification of diverticulosis, location of polyp resection, and presence of hemorrhoids. Pretreatment CS findings were then correlated with outcomes following SBRT. RESULTS: Identification of comorbid GI conditions was a common event, with the presence of diverticulosis in 49.5% (n = 100), hemorrhoids in 67% (n = 136), and polyps in 48% (n = 98). More than half of patients with polyps removed had at least 1 removed from the rectosigmoid. Pretreatment CS did not introduce a delay in SBRT start date. Grade 1 toxicity was significantly lower in patients who underwent CS closer to the initiation of SBRT. There was no increased risk of physician-graded toxicity in the presence of diverticulosis, hemorrhoids, or polyps. Patient-reported GI QoL pattern in our screening cohort mimicked that seen in the previously published nonscreened population. There was no overt QoL detriment observed in patients who had GI pathology identified before SBRT. CONCLUSIONS: GI pathology identified in our elderly patient population was commonly identified on pretreatment CS. Screening CS may optimize bowel health for patients heading into radiation therapy. Toxicity and QoL for patients with GI pathologies identified on pretreatment CS do not preclude the delivery of prostate SBRT. We advocate for pretreatment CS in patients eligible prior to SBRT.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lischalk JW, Santos VF, Vizcaino B, et al. Screening Colonoscopy Association With Gastrointestinal Toxicity and Quality of Life After Prostate Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2025. PMID: 40276629. doi:10.1016/j.adro.2025.101747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。